Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA
MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced the acquisition of Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA for €5.15m in cash and shares.
The acquisition of ANMI significantly expands the market opportunity for Telix’s investment in prostate cancer imaging and builds on the existing commercialization collaboration for the illumetTM prostate imaging (68Ga-PSMA) kit for the US market. Combining the resources, clinical data and human capital of both companies is expected to accelerate the process of preparing a new drug application (NDA) in the United States and Europe for prostate imaging.
Telix CEO Christian Behrenbruch stated, “The acquisition of ANMI creates a significantly more capable company with the ability to deliver prostate cancer imaging on a global basis, rather than in a territorially-segmented manner. The clinical availability of prostate cancer imaging will have a major impact on the adoption rate of PSMA radiotherapeutics and therefore this acquisition reinforces our competitive differentiation of offering both imaging and therapy as an integrated solution. We’re very pleased to welcome the talented ANMI team to Telix.”
ANMI Co-Founder and CEO Ludovic Wouters noted, “ANMI and Telix have achieved a great deal as business partners over the past two years. With the growing importance of nuclear medicine, particularly in urologic oncology, the two companies benefit from establishing an integrated theranostic approach. We also see a clear way for ANMI to contribute to Telix’s product development by packaging their therapeutic products in way that makes them fast and easy to prepare in the radiopharmacy setting.”
The transaction is expected to complete in December 2018. Financial details of the transaction are available: https://www.asx.com.au/asx/share-price-research/company/TLX.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (Japan) and Indianapolis (USA). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.
About Advanced Nuclear Medicine Ingredients (ANMI) SA
ANMI SA is a pharmaceutical company developing innovative radiopharmaceutical solutions and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the scalable synthesis of “theranostic” (therapeutic + diagnostic) radiopharmaceuticals and to ease their daily production in hospitals and radiopharmacies. ANMI's vision is focused on increasing patient access to new highly specific theranostic radiopharmaceuticals through streamlined and cost-effective production processes. For more information visit www.anmi.be.
About Prostate-Specific Membrane Antigen (PSMA)
PSMA is a cancer target (cell surface antigen) that is highly upregulated in prostate cancer cells and is a highly validated and promising target for a range of diagnostic and therapeutic strategies in prostate cancer.
About HBED-CC-PSMA-11 (68Ga-PSMA)
HBED-CC-PSMA-11 (68Ga-PSMA) is a small molecule (ligand) that targets and binds to PSMA and enables metastatic prostate cancer to be imaged using Positron Emission Tomography (PET) with excellent sensitivity and specificity. PET is a highly effective and widely used imaging modality in the management of cancer.
About the 68Ga-PSMA Kit (illumetTM )
ANMI’s 68Ga-PSMA kit is the first “cold kit” for direct labelling of a PSMA-targeting molecule with 68Ga (gallium). The kit utilizes proprietary chemistry to enable robust and reliable radiolabeling at room temperature in 5 minutes. The 68Ga-PSMA kit is currently in late-stage clinical development in Europe and is commercialized in the US by Telix Pharmaceuticals (US) Inc. where it is marked under the brand name illumetTM .
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorization in any jurisdiction, including the United States and Europe.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
SoftServe Documentary Receives “The Best Corporate Media of Ukraine 2018” Award17.12.2018 13:00 | Pressemelding
25th anniversary documentary takes prize in “The Best Corporate Movie” category AUSTIN, Texas, Dec. 17, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces the Ukrainian Association of Corporate Media, a public organization uniting professionals in the field of marketing, PR, journalism, and advertising, recognized SoftServe in its annual competition – “The Best Corporate Media of Ukraine 2018.” SoftServe’s 25th anniversary documentary took second place in the “The Best Corporate Movie Category.” The documentary honors the company’s 25th anniversary with an inside look at how SoftServe evolved over the past quarter century to become a leading digital authority. In the documentary, SoftServe’s founders and leadership share their inspiring stories and highlight the company’s achievements over the years. “It is a great honor to receive this recognition from the Ukrainian Association of Corporate Media for our 25th anniversary documentary,” sai
Bombardier to supply a further 20 FLEXITY trams to Karlsruhe17.12.2018 10:00 | Pressemelding
Albtal-Verkehrs-Gesellschaft expands its fleet to 62 trams The dual-system vehicles operate on both the tram network and regional railway network BERLIN, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Global mobility solution provider Bombardier Transportation received a call-off order from Albtal-Verkehrs-Gesellschaft mbH (AVG), the transport company of the Alb valley region in southwest Germany, for the delivery of 20 further dual-system BOMBARDIER FLEXITY trams. This third order is based on a framework agreement for a total of 75 vehicles from 2009. The order is valued at approximately 87 million euro ($98 million US). The vehicles will be delivered between May 2020 and March 2021. "Striving to provide attractive local transport services, we have decided to order 20 additional dual-system vehicles from Bombardier Transportation. This will allow us to purposefully enlarge our vehicle fleet offering high-quality standards to our passengers," said Dr. Alexander Pischon, CEO of Albtal-Verkehrs-Gesel
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding
SoftServe Achieves Machine Learning Specialization in Google Cloud Partner Program14.12.2018 13:00 | Pressemelding
Google Cloud recognizes SoftServe’s technical proficiency and proven success AUSTIN, Texas, Dec. 14, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it achieved the Machine Learning Partner Specialization in the Google Cloud Premier Partner Program. The Partner Specialization affirms SoftServe’s expertise and success building customer solutions in the machine learning field using Google Cloud Platform (GCP) technology. The Google Cloud Partner Specialization Program is designed to provide Google Cloud customers with qualified partners that demonstrate technical proficiency in the specialized solution and service areas. Specifically, the Machine Learning Specialization demonstrates SoftServe’s expertise in data exploration, preprocessing, model training, model evaluation, model deployment, online prediction, and Google Cloud’s pre-trained machine learning APIs. “We teach machines to learn, read, see and understand business data, and make
Minerals Technologies Announces Price Increases for Specialty Minerals Products in Europe14.12.2018 00:01 | Pressemelding
NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Specialty Minerals Inc. (“SMI”), a subsidiary of Minerals Technologies Inc., announced today that effective February 1, 2019, it will increase prices by up to 10% for all coated ultrafine precipitated calcium carbonate (PCC) from SMI’s Lifford Specialty PCC facility in Birmingham, UK, subject to individual customer contracts and market provisions. The price increases reflect increased market demand for higher performance materials, as well as significant inflation in input, raw material and logistics costs. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. (MTI) is a resource- and technology-based growth company that develops, produces and markets worldwide a broad range of specialty mineral, mineral-based and synthetic mineral products and related systems and services. MTI serves the paper, foundry, steel, construction, environmental, energy, polymer and consumer products industries. The Company reported sales of $1.